Dyne Therapeutics, Inc. (DYN)

About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Headquarters: Waltham, MA, US · Employees: 263 · Website: https://www.dyne-tx.com

Frequently asked questions about Dyne Therapeutics, Inc. (DYN)

What is Dyne Therapeutics, Inc. (DYN)?

Dyne Therapeutics, Inc. (DYN) is a publicly traded company in the Pharmaceutical Preparations sector (Biotechnology), listed on Nasdaq. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.